Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.

Also called NCT06030544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Spanish National Research Council (from the registry)
Registry
  • NCT NCT06030544
Other papers using this trial's data
  • Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial Diabetes, obesity & metabolism, 2026-11 DOI, PubMed 42608317, PMC13646337 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06030544. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-25 (actual); primary completion 2025-03-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)
Acronym
OLTRAD
Condition
Diabetic Patients
Condition
Type II Diabetes Mellitus
Intervention (Dietary supplement)
OA-enriched functional olive oil
Intervention (Dietary supplement)
commercial olive oil
Lead sponsor
Spanish National Research Council (class: other government)
Collaborator
Andalusian Health Service (class: other government)
Collaborator
Universidad Pablo de Olavide (class: other)

Record details

Record id
cardio:ct-nct06030544
Content hash
01810661ce70da2ecff756b0a5043f20eed80b6e0fb3e1579b535a8fc1a87280